Abstract 580P
Background
Primary tumor location (PTL) is a well-established prognostic factor in stage III and IV colorectal cancer (CRC), with right-sided CRC (RSCC) showing a worse prognosis compared to left-sided CRC (LSCC). However, the impact of PTL on stage II CRC remains uncertain. One explanation for these inconsistencies is the potential confounding effect of molecular biomarkers, such as MMR status. Therefore, there is a need to elucidate the prognostic value of PTL, as well as the role of biomarkers in this effect.
Methods
This study utilized observational data from a retrospective cohort obtained from the Belgian Cancer Registry (BCR). The study population comprised all patients diagnosed with pathologically confirmed stage II CRC in Belgium from January 1st, 2015, to December 31st, 2016 (n= 3,278). Information on PTL, demographics, pathologic T category (pT category), and molecular biomarkers (including MMR status, BRAF and KRAS mutations) was collected from the registry, along with vital status to calculate overall survival (OS). The primary aim of this study was to investigate the independent prognostic value of PTL in stage II CRC. Additionally, we assessed whether potential confounding factors, such as biomarkers and demographics, influenced the prognostic effect of PTL.
Results
In the univariate analysis, patients with stage II RSCC had a significantly worse OS compared to those with LSCC (including rectal cancer; p-value=0.0055 and excluding rectal cancer; p-value=0.0035). Higher age and pT4 were also significantly associated with worse OS. However, in the multivariable analysis, only gender, age, and pathologic T-stage were found to be significant predictors of OS. PTL was not a significant factor in multivariable analysis. Furthermore, biomarkers such as MMR-status, BRAF-, and KRAS mutations did not show a significant effect on OS in either analysis.
Conclusions
Our analysis led us to the conclusion that PTL is not an independent prognostic factor in stage II. Notably, we observed confounding effects between patient characteristics and the prognostic impact of PTL, such as older age at diagnosis and shorter OS in patients with RSCC. Furthermore, molecular biomarkers did not have a statistically significant effect on OS in stage II CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Antwerp.
Funding
Antwerp University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10